This site is for healthcare professionals only. If you are not a healthcare professional please click here
Prescribing information and adverse event reporting information can be found at the bottom of this webpage.

Astellas GU Masterclass: PADCEVTM▼(enfortumab vedotin)

Day 1 | Friday 4 July 2025, 8:30–16:25 CEST

Day 1 – Bladder Cancer

Day 1 co-Chair summary

Tom Powles, Oncologist, UK

Michiel van der Heijden, Oncologist, Netherlands

Plenary slides

padcev
Session 1 – Maximising outcomes in advanced UC: The critical importance of putting first things 1st

Ignacio Durán, Oncologist, Spain

Panel discussion and Q&A, moderated by Tom Powles

15 minutes

The evolution of the 1L treatment landscape in unresectable/mUC and the importance of 1L treatment choice

padcev
padcev
Session 1 – Maximising outcomes in advanced UC: The critical importance of putting first things 1st

Gunhild von Amsberg, Oncologist, Germany

Panel discussion and Q&A, moderated by Tom Powles

15 minutes

The evolution of the 1L treatment landscape in unresectable/mUC and the importance of 1L treatment choice

padcev
padcev
Session 2 – Deeper insights: What the latest data tells us about today’s SOC for advanced UC

Shilpa Gupta, Oncologist, US

Tom Powles, Oncologist, UK

Panel discussion and Q&A moderated by Tom Powles

45 minutes

An overview of the latest EV-302 data, including efficacy and safety outcomes in specific subgroup populations

padcev
padcev
Session 3 – Biomarkers in advanced UC: Current insights and future directions

Rob Jones, Oncologist, UK

Eva Compérat, Oncologist, Austria

Panel discussion and Q&A moderated by Tom Powles

35 mins

An overview of current and future biomarkers in UC

padcev
padcev
Session 4 – Part 1 | Managing baseline comorbidities and staying ahead of AEs with EV (plenary)

Ignacio Durán, Oncologist, Spain

10 mins

Strategies to optimise treatment response with EV+P

padcev
padcev
Session 4 – Part 1 | Managing baseline comorbidities and staying ahead of AEs with EV (plenary)

Patrizia Giannatempo, Oncologist, Italy

10 minutes

Management strategies for AESIs associated with EV+P and the importance of patient education

padcev
session 4
Session 4 – Part 1 | Managing baseline comorbidities and staying ahead of AEs with EV (plenary)

Michiel van der Heijden, Oncologist, Netherlands

10 minutes

Tips for initiating treatment with EV+P

session 4
padcev
Session 4 – Part 2 | Managing baseline comorbidities and staying ahead of AEs with EV (workshop activity)

Yohann Loriot, Oncologist, France
Vadim Koshkin, Oncologist, US


20 minutes

A case study involving a patient who is frail and is receiving treatment with EV+P

padcev
padcev
Session 4 – Part 2 | Managing baseline comorbidities and staying ahead of AEs with EV (workshop activity)

Rob Jones, Oncologist, UK

Aisling Carr, Neurologist, UK

20 minutes

A case study exploring the management of EV+P-related peripheral neuropathy, with expert insights from a neurologist

padcev
padcev
Session 4 – Part 2 | Managing baseline comorbidities and staying ahead of AEs with EV (workshop activity)

Patrizia Giannatempo, Oncologist, Italy

Giovanni Damiani, Dermatologist, Italy

20 minutes

A case study exploring the management of EV+P-related skin toxicities, with expert insights from a dermatologist

padcev
padcev
Session 4 – Part 2 | Managing baseline comorbidities and staying ahead of AEs with EV (workshop activity)

Dora Niedersüß-Beke, Oncologist, Austria

Gunhild von Amsberg, Oncologist, Germany

20 minutes

A case study highlighting practical guidance with EV+P regarding pre-initiation and monitoring considerations

padcev
padcev
Session 5 – Patient case studies: Navigating challenging clinical scenarios

Yohann Loriot, Oncologist, France
20 minutes

A case study involving a patient with rare histological subtypes/mixed histology

padcev
padcev
Session 5 – Patient case studies: Navigating challenging clinical scenarios

Jens Bedke, Oncologist, Germany
20 minutes

A case study exploring treatment considerations for patients with unresectable/mUC who have previously received adjuvant immunotherapy

padcev
padcev
Session 5 – Patient case studies: Navigating challenging clinical scenarios

Shilpa Gupta, Oncologist, US
20 mins

A case study to discuss 2L treatment options for patients with unresectable/mUC following 1L EV+P

padcev
padcev
Session 7 – Conclusions drawn from RWE: Exploring real-world use of EV monotherapy and EV+P

Vadim Koshkin, Oncologist, US

Dora Niedersüß-Beke, Oncologist, Austria

Panel discussion and Q&A moderated by
Michiel van der Heijden

35 mins

A summary of real-world use of EV monotherapy and EV+P in the US and EU

padcev

Prescribing Information

UK Prescribing Information is available for PADCEV™▼(enfortumab vedotin) here. Dutch Prescribing Information for PADCEV™▼(enfortumab vedotin) is available here.

PADCEV indications:

  • EV, in combination with P, is indicated for the 1L treatment of adult patients with unresectable/mUC who are eligible for platinum-containing chemotherapy
  • EV as monotherapy is indicated for the treatment of adult patients with LA/mUC who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor

▼This medicinal product is subject to additional monitoring.

AE reporting information

NL: Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Nederland: Nederlands Bijwerkingen Centrum Lareb;
Website: www.lareb.nl

UK: Adverse events should be reported.

Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for ‘MHRA yellow card’ in the Google Play Store or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd on 0800 783 5018

EV, in combination with P, has received EMA approval for the 1L treatment of adult patients with unresectable/mUC who are eligible for platinum-containing chemotherapy. Please note: Reimbursement in some EU countries is still pending.

1L, first line; AE, adverse event; AESI, adverse event of special interest; EMA; European Medicines Agency; European Union; EV, enfortumab vedotin; mUC, metastatic urothelial carcinoma; P, pembrolizumab; RWE, real-world evidence; SOC, standard of care; UC, urothelial carcinoma.